Medicare Coverage for GLP-1 Medications: Understanding the 2026 Part D Expansion and Your Eligibility

The Treat and Reduce Obesity Act and subsequent legislative provisions have fundamentally altered Medicare's approach to anti-obesity pharmacotherapy. Historically, Medicare Part D explicitly excluded coverage for medications used solely for weight loss, creating a significant coverage gap for the estimated 42 percent of Medicare beneficiaries living with obesity. The legislative changes taking effect in the 2025-2026 plan years have begun to reverse this exclusion, allowing Part D plans to cover FDA-approved anti-obesity medications for qualifying beneficiaries.

Under the expanded framework, Medicare Part D plans may now include GLP-1 receptor agonists prescribed for chronic weight management on their formularies. This applies to semaglutide (Wegovy) at the 2.4 mg weekly dose approved for obesity, and tirzepatide (Zepbound) at approved weight management doses. Importantly, the legislation grants Part D plans discretion in how they implement coverage, meaning formulary placement, cost-sharing tiers, prior authorization requirements, and utilization management criteria vary significantly between plans.

Medicare beneficiaries with type 2 diabetes have had access to GLP-1 medications under Part D for several years, as Ozempic and Mounjaro carry diabetes indications that were never subject to the weight loss exclusion. The new legislative changes specifically expand access for beneficiaries whose primary indication is obesity without a concurrent diabetes diagnosis. This distinction is clinically important because the weight management doses of semaglutide and tirzepatide differ from diabetes doses, and the obesity-labeled products (Wegovy and Zepbound) have different formulary status than their diabetes-labeled counterparts. Beneficiaries should carefully evaluate their Part D plan options during annual enrollment to identify plans that offer the most favorable GLP-1 coverage for their specific clinical indication.

Medicare Part D coverage for anti-obesity GLP-1 medications requires beneficiaries to meet specific qualifying criteria that mirror FDA-approved labeling. Generally, plans require a documented BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Some plans additionally require documentation of failed structured lifestyle intervention lasting at least three to six months.

Enrollment timing matters significantly. Medicare Part D plans publish their formularies before each annual enrollment period, which runs from October 15 through December 7 for coverage beginning January 1 of the following year. Beneficiaries interested in GLP-1 coverage should review available Part D plan formularies during this window using the Medicare Plan Finder tool at Medicare.gov. Comparing plans based on GLP-1 tier placement, estimated annual out-of-pocket costs, and prior authorization requirements can result in significant cost differences across available plans in the same geographic area.

Beneficiaries already enrolled in a Part D plan that does not cover anti-obesity medications may need to wait until the next annual enrollment period to switch plans, unless they qualify for a Special Enrollment Period triggered by events such as moving to a new service area, losing other creditable coverage, or qualifying for Extra Help. Medicare Advantage plans with integrated Part D coverage follow the same formulary rules but may offer additional supplemental benefits related to obesity management, including coverage for nutritional counseling, fitness programs, or meal delivery services that complement pharmacotherapy and support sustained weight management outcomes.

Even with Part D coverage, Medicare beneficiaries should anticipate meaningful out-of-pocket costs for GLP-1 medications due to the Part D benefit structure. The standard Part D benefit in 2026 includes an annual deductible, an initial coverage phase with cost-sharing, and a catastrophic coverage phase. GLP-1 medications are typically placed on specialty tiers (Tier 4 or 5), where beneficiary cost-sharing ranges from 25 to 33 percent of the negotiated price during the initial coverage phase.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D prescription costs, which took effect in 2025, provides critical financial protection for Medicare beneficiaries using GLP-1 medications. Once a beneficiary's total out-of-pocket spending reaches $2,000 in a calendar year, they pay nothing for additional covered prescriptions for the remainder of the year. For beneficiaries on GLP-1 therapy, this cap is typically reached within the first two to four months of treatment, meaning the remaining eight to ten months of medication are effectively covered at no additional cost.

Medicare's Part D Prescription Payment Plan, also introduced under the IRA, allows beneficiaries to spread their out-of-pocket costs across monthly installments throughout the year rather than paying large amounts upfront when filling prescriptions. This smoothing mechanism means a beneficiary facing $2,000 in annual out-of-pocket costs can budget approximately $167 per month rather than absorbing the full cost-sharing amount during the initial fills. Beneficiaries should contact their Part D plan directly to enroll in the monthly payment option and understand how it interacts with their specific plan design and formulary structure.

Medicaid coverage for GLP-1 medications varies dramatically by state, creating a patchwork of access that depends heavily on geography. As of 2026, approximately 20 states cover at least one GLP-1 medication for weight management under their Medicaid formularies, though most impose stringent prior authorization criteria. States with broader coverage tend to include those that have expanded Medicaid under the Affordable Care Act and have higher obesity prevalence rates.

Dual-eligible beneficiaries, those who qualify for both Medicare and Medicaid, face a particularly complex coverage landscape. Their prescription drug coverage is primarily managed through Medicare Part D Low-Income Subsidy (LIS) plans rather than Medicaid, meaning the Part D formulary and coverage rules apply. Dual-eligible beneficiaries receive premium and cost-sharing subsidies through the Extra Help program, which can reduce copays for covered medications to $0 to $4.50 per prescription in 2026, depending on income level. If a GLP-1 medication is on their assigned Part D plan's formulary, dual-eligible beneficiaries may access these medications at minimal out-of-pocket cost.

For Medicare beneficiaries in states where Medicaid does not cover anti-obesity medications, or whose Part D plans do not include GLP-1s on formulary, alternative access pathways become important. Compounded GLP-1 medications through telehealth platforms like Weight Method, at $297 per month for semaglutide and $349 per month for tirzepatide, offer a predictable cost structure outside the insurance system. While these costs are not covered by Medicare, they can be paid using personal funds, and the all-inclusive pricing may compare favorably to Part D cost-sharing for beneficiaries who have not yet reached the out-of-pocket cap.

Medicare Supplement Insurance (Medigap) policies do not cover prescription drugs and therefore do not help with GLP-1 medication costs. However, Medicare Advantage plans, which combine Part A, Part B, and typically Part D coverage, may offer supplemental benefits relevant to obesity management. Some Medicare Advantage plans include coverage for comprehensive metabolic health programs, registered dietitian consultations, gym memberships or fitness incentives, and telehealth services that complement pharmacotherapy. When comparing Medicare Advantage plans during annual enrollment, beneficiaries should evaluate both the Part D formulary for GLP-1 coverage and the supplemental benefits that support a holistic approach to weight management.

The future trajectory of Medicare GLP-1 coverage appears favorable. Congressional interest in expanding anti-obesity medication access continues to grow, driven by the dual arguments of improved health outcomes and long-term cost savings. The Congressional Budget Office has modeled scenarios in which broader Medicare coverage of anti-obesity medications reduces spending on obesity-related complications, including type 2 diabetes management, joint replacements, cardiovascular events, and certain cancers, partially offsetting the direct drug costs.

Beneficiaries should stay informed about annual formulary changes by reviewing plan notices during the Annual Notice of Change period each September, which details any modifications to drug coverage, cost-sharing, or prior authorization requirements for the upcoming plan year. Working with a State Health Insurance Assistance Program (SHIP) counselor, available free in every state, can help beneficiaries navigate plan comparisons and identify the most cost-effective coverage option for their medication needs. For beneficiaries who cannot wait for or obtain Medicare coverage, Weight Method provides immediate access to GLP-1 therapy with transparent monthly pricing and clinical support.